×
About 4,288 results

ALLMedicine™ Polycystic Kidney Disease Center

Research & Reviews  1,573 results

To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211 in Healthy Volunteers and Autosomal Dominant Polycystic Kidney Disease Subjects
https://clinicaltrials.gov/ct2/show/NCT04908462

May 20th, 2022 - This study is a Phase 1, first in human (FIH), randomized, double-blind, placebo-controlled study of AL01211 in healthy adult participants The study consists of two parts: Part A will investigate the safety, tolerability, pharmacokinetics, and pha...

Genetics, pathobiology and therapeutic opportunities of polycystic liver disease.
https://doi.org/10.1038/s41575-022-00617-7 10.1016/j.jhep.2017.11.024 10.1038/nrgastro.2014.155 10.4254/wjh.v12.i3.72 10.1111/j.1572-0241.2005.00263.x 10.1111/j.1478-3231.2010.02247.x 10.1002/hep.29582 10.1002/cld.1001 10.1177/2050640617705577 10.1080/17474124.2017.1309280 10.1016/j.jhepr.2020.100166 10.1038/ki.2009.128 10.1186/s12882-015-0002-z 10.1111/liv.13965 10.1111/j.1432-2277.2011.01360.x 10.1111/tri.12875 10.2215/CJN.00080605 10.1111/liv.14986 10.1002/cpt.1553 10.1016/0092-8674(94)90137-6 10.1002/hep.1840110619 10.1126/science.272.5266.1339 10.1681/ASN.2019030298 10.1016/j.ajhg.2018.03.013 10.1016/j.kint.2020.02.022 10.1016/j.ajhg.2016.05.004 10.1186/s13023-020-01585-4 10.1038/ejhg.2015.86 10.1038/ng833 10.1038/ng.3871 10.1016/j.ejmg.2021.104160 10.1038/ng1104 10.1038/ng1357 10.1172/JCI90129 10.1002/humu.23383 10.1073/pnas.1309438111 10.21037/atm-20-3318 10.1172/JCI76972 10.1152/ajpgi.00064.2006 10.1038/ncb754 10.1073/pnas.0610324104 10.1074/jbc.M510082200 10.1093/hmg/ddl404 10.1016/j.devcel.2009.06.016 10.1038/s41575-018-0075-9 10.1038/ncb3363 10.1002/hep.26554 10.3389/fphys.2017.00887 10.1146/annurev-biophys-050511-102312 10.1074/jbc.REV118.002804 10.1016/j.bbamcr.2013.04.001 10.2174/1389203716666150213160438 10.1016/j.semcdb.2014.12.001 10.1038/ng.860 10.1074/jbc.M107788200 10.1038/nrgastro.2012.254 10.1016/j.molmed.2014.01.003 10.1002/hep.24292 10.1146/annurev-pathmechdis-012418-013013 10.3748/wjg.v19.i35.5775 10.1053/j.gastro.2011.08.004 10.1371/journal.pone.0132295 10.1002/hep.1840400404 10.2353/ajpath.2007.070337 10.1002/path.2734 10.1002/dvdy.21520 10.1038/nature07753 10.1038/ki.2010.375 10.1016/j.cell.2011.05.030 10.1242/dev.054452 10.1242/dev.078634 10.1002/hep.21952 10.1186/2046-2530-1-7 10.1681/ASN.2006121355 10.1242/dev.129.8.1819 10.1016/j.ydbio.2007.05.028 10.1053/j.gastro.2005.12.005 10.1172/JCI0214099 10.1172/JCI200420083 10.1038/sj.emboj.7600160 10.1242/dev.02591 10.1053/j.gastro.2008.12.006 10.1016/S1665-2681(19)31406-1 10.1097/MOG.0000000000000514 10.1038/ejhg.2016.97 10.34067/KID.0002522020 10.1371/journal.pone.0050324 10.1136/gutjnl-2014-308062 10.3748/wjg.v19.i1.141 10.1681/ASN.V1071524 10.1016/S1097-2765(00)80135-5 10.1055/s-0036-1597817 10.1053/j.gastro.2006.07.003 10.2353/ajpath.2008.080125 10.1016/j.jhep.2016.10.032 10.1002/hep.22636 10.1053/j.gastro.2010.04.010 10.1016/j.jhep.2015.05.023 10.1053/j.gastro.2006.12.039 10.1002/hep.26140 10.1159/000450989 10.2174/1389200216666151103115454 10.1002/hep.29284 10.1136/gutjnl-2015-309458 10.1016/S0002-9440(10)62231-6 10.1111/j.1523-1755.2004.00952.x 10.1002/hep.21143 10.1152/ajpcell.00038.2007 10.1053/j.gastro.2009.09.005 10.1002/hep.23511 10.2353/ajpath.2008.070293 10.1093/ndt/gfq384 10.1371/journal.pone.0087660 10.1053/jhep.2002.34741 10.1002/hep.23386 10.1038/s41598-017-16686-7 10.3748/wjg.v12.i22.3496 10.17235/reed.2016.3980/2015 10.1152/ajprenal.00242.2012 10.1016/j.clinre.2018.03.009 10.1111/joim.12645 10.1038/nm935 10.1681/ASN.2004121090 10.1038/labinvest.2016.93 10.1159/000477664 10.1038/s41575-019-0125-y 10.1152/ajpgi.90265.2008 10.1073/pnas.0705964104 10.1083/jcb.201101005 10.1186/s13630-015-0021-1 10.1016/j.gastro.2003.09.001 10.1016/S0002-9440(10)63427-X 10.2353/ajpath.2010.090658 10.1002/path.5685 10.1038/ng.2715 10.1016/j.kint.2020.05.049 10.34067/KID.0001022019 10.1016/j.ajpath.2013.09.021 10.1016/j.cell.2014.03.061 10.1016/j.cell.2007.04.035 10.1016/j.ajpath.2013.11.027 10.1016/j.ajpath.2017.12.016 10.1002/hep.31216 10.1016/j.kint.2016.05.031 10.1074/jbc.M117.803775 10.1152/ajprenal.00186.2017 10.1086/368295 10.1111/liv.14485 10.1038/s41580-018-0068-0 10.1073/pnas.2007194118 10.1016/j.jhep.2020.09.010 10.1002/ueg2.12126 10.1002/hep.28933 10.1002/hep.29577 10.4161/auto.7.7.15822 10.1038/s41467-020-18794-x 10.1172/JCI93557 10.1242/dev.175596 10.1016/j.devcel.2010.01.011 10.1038/nbt.3294 10.1016/j.bbrc.2016.04.075 10.1038/s41598-018-30433-6 10.1038/nbt.3275 10.1136/gutjnl-2013-305281 10.1002/hep.28382 10.1016/j.cellimm.2015.01.018 10.1002/hep.24036 10.1007/s10620-007-0121-x 10.1016/j.crad.2019.08.009 10.4103/0366-6999.211882 10.1016/j.radcr.2021.04.066 10.1007/s11605-007-0376-8 10.1111/hepr.12560 10.1016/j.transproceed.2008.02.080 10.1111/liv.13041 10.1016/j.mayocp.2015.05.011 10.1111/j.1365-2036.2011.04923.x 10.1111/liv.12726 10.1016/j.cgh.2015.12.049 10.1016/j.cgh.2015.05.039 10.1053/j.gastro.2019.04.018 10.1053/j.gastro.2013.04.055 10.1136/bmjopen-2019-032620 10.2215/CJN.13661119 10.1007/s00330-017-5205-1 10.1111/apt.13301 10.1146/annurev-pharmtox-010818-021059 10.1016/j.jhep.2016.05.009 10.1111/1744-9987.12326 10.1681/ASN.2004080660 10.1093/ndt/gfi181 10.1073/pnas.0509694103 10.3748/wjg.v23.i30.5499 10.1056/NEJMoa0907419 10.1056/NEJMoa1003491 10.1681/ASN.2007050626 10.1016/j.jhep.2013.03.004 10.1097/MD.0000000000026797 10.1681/ASN.2012070650 10.1111/cge.13249 10.1007/s12072-021-10176-9 10.3389/fped.2017.00221 10.1152/ajprenal.00352.2017 10.1371/journal.pone.0081480 10.1152/ajpgi.00120.2020 10.1249/MSS.0000000000002251 10.1172/JCI34922 10.1016/j.jhepr.2021.100345 10.1681/ASN.2017050483 10.1016/S0140-6736(18)32782-X 10.1038/s41575-019-0156-4 10.1038/s41572-018-0047-y 10.1016/j.ydbio.2009.10.025 10.1002/hep.25872 10.1053/j.gastro.2011.11.036 10.1152/ajprenal.00460.2010 10.1111/j.1523-1755.2005.00395.x
Nature Reviews. Gastroenterology & Hepatology; Olaizola P, Rodrigues PM et. al.

May 14th, 2022 - Polycystic liver diseases (PLDs) are inherited genetic disorders characterized by progressive development of intrahepatic, fluid-filled biliary cysts (more than ten), which constitute the main cause of morbidity and markedly affect the quality of ...

HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life
https://clinicaltrials.gov/ct2/show/NCT05373264

May 13th, 2022 - Aims: The main objectives of the current study are to prospectively test whether HCT co-treatment can improve V2RA efficacy (slowing kidney function decline) and tolerability (quality of life) in PKD. Study design: Investigator driven randomized p...

Ambulatory pulse pressure and its contributors in autosomal dominant polycystic kidney ...
https://doi.org/10.17219/acem/149373
Advances in Clinical and Experimental Medicine : Official... Koska-Ścigała A, Jankowska M et. al.

May 12th, 2022 - Pulse pressure (PP) is a pulsatile component of blood pressure (BP), strongly correlated with arterial stiffness (AS) and impacting prognosis. Disproportionally increased PP values in individuals with autosomal dominant polycystic kidney disease (...

Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD
https://clinicaltrials.gov/ct2/show/NCT03203642

May 12th, 2022 - Safety and efficacy of 50mg tesevatinib in comparison to placebo in patients with autosomal dominant polycystic kidney disease (ADPKD) will be assessed. The primary purpose of this study is focused on evaluating the change from baseline in height-...

see more →

Guidelines  14 results

A digest from evidence-based Clinical Practice Guideline for Polycystic Kidney Disease ...
https://doi.org/10.1007/s10157-021-02097-6
Clinical and Experimental Nephrology; Nishio S, Tsuchiya K et. al.

Sep 27th, 2021 - A digest from evidence-based Clinical Practice Guideline for Polycystic Kidney Disease 2020.|2021|Nishio S,Tsuchiya K,Nakatani S,Muto S,Mochizuki T,|diagnosis,genetics,therapy,diagnosis,drug therapy,

International consensus statement on the diagnosis and management of autosomal dominant...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136168
Nature Reviews. Nephrology; Gimpel C, Bergmann C et. al.

May 24th, 2019 - These recommendations were systematically developed on behalf of the Network for Early Onset Cystic Kidney Disease (NEOCYST) by an international group of experts in autosomal dominant polycystic kidney disease (ADPKD) from paediatric and adult nep...

Clinical practice guideline monitoring children and young people with, or at risk of de...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6489289
BMC Nephrology; Dudley J, Winyard P et. al.

May 2nd, 2019 - Autosomal Dominant Polycystic Kidney Disease (ADPKD) is thought to affect about 1 in 1000 people in the UK. ADPKD causes a progressive decline in kidney function, with kidney failure tending to occur in middle age. Children and young people with A...

Evidence-based clinical practice guidelines for polycystic kidney disease 2014.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4956721
Clinical and Experimental Nephrology; Horie S, Mochizuki T et. al.

Apr 21st, 2016 - Evidence-based clinical practice guidelines for polycystic kidney disease 2014.|2016|Horie S,Mochizuki T,Muto S,Hanaoka K,Fukushima Y,|diagnosis,epidemiology,therapy,diagnosis,epidemiology,genetics,therapy,

KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Diet and Lifestyle Man...
https://doi.org/10.1016/j.semnephrol.2015.10.008
Seminars in Nephrology; Campbell KL, Rangan GK et. al.

Jan 1st, 2016 - KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Diet and Lifestyle Management.|2016|Campbell KL,Rangan GK,Lopez-Vargas P,Tong A,|administration & dosage,administration & dosage,physiology,complications,physiopathology,therapy,admi...

see more →

Drugs  4 results see all →

Clinicaltrials.gov  42 results

To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211 in Healthy Volunteers and Autosomal Dominant Polycystic Kidney Disease Subjects
https://clinicaltrials.gov/ct2/show/NCT04908462

May 20th, 2022 - This study is a Phase 1, first in human (FIH), randomized, double-blind, placebo-controlled study of AL01211 in healthy adult participants The study consists of two parts: Part A will investigate the safety, tolerability, pharmacokinetics, and pha...

HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life
https://clinicaltrials.gov/ct2/show/NCT05373264

May 13th, 2022 - Aims: The main objectives of the current study are to prospectively test whether HCT co-treatment can improve V2RA efficacy (slowing kidney function decline) and tolerability (quality of life) in PKD. Study design: Investigator driven randomized p...

Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD
https://clinicaltrials.gov/ct2/show/NCT03203642

May 12th, 2022 - Safety and efficacy of 50mg tesevatinib in comparison to placebo in patients with autosomal dominant polycystic kidney disease (ADPKD) will be assessed. The primary purpose of this study is focused on evaluating the change from baseline in height-...

Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease
https://clinicaltrials.gov/ct2/show/NCT04152837

May 10th, 2022 - This is a Phase 3, open-label, repeat-dose study designed to assess liver safety, non-liver safety, and efficacy in subjects who previously experienced liver chemistry test abnormalities while treated with tolvaptan and were permanently discontinu...

Transformative Research in Diabetic Nephropathy
https://clinicaltrials.gov/ct2/show/NCT02986984

Mar 8th, 2022 - Progress in the area of diabetic kidney research leading to new therapeutics development has been very limited. Indeed, no new medicines indicated for the treatment of chronic kidney disease (CKD) have been approved since ARB's have become standar...

see more →

News  63 results

Mayo Classification by Ultrasound Useful in Predicting Rapid Progression of Rare Kidney Disease
https://www.medscape.com/viewarticle/966321

Jan 11th, 2022 - NEW YORK (Reuters Health) - The Mayo classification (MC) of autosomal dominant polycystic kidney disease (ADPKD) based on ultrasound rather than magnetic resonance imaging (MRI) findings performs well, especially at the extremes of the MC (classes...

Kidney Donors Reveal What It's Like to Match for Surgery
https://www.medscape.com/viewarticle/962376

Nov 5th, 2021 - From the time they were young, Amy DeAngelis and her younger sister Laura Johnson knew that Laura would need a new kidney someday. A condition called polycystic kidney disease runs in their family, and eventually the affected organs fail. Amy had ...

Fast Five Quiz: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
https://www.medscape.com/viewarticle/954016

Aug 6th, 2021 - Autosomal-dominant polycystic kidney disease (ADPKD) is the most common hereditary renal disease and the fourth leading cause of end-stage renal disease worldwide. As many as 12 million people are affected by ADPKD, which stems primarily from muta...

Fast Five Quiz: Autosomal Dominant Polycystic Kidney Disease Presentation and Diagnosis
https://www.medscape.com/viewarticle/950557

Jun 29th, 2021 - Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease worldwide. It is characterized by progressive development of renal cysts, hypertension, and destruction of the kidney parenchyma. Most patients with ...

Prolonged Antibiotics Cut Risk of Recurrence in Polycystic Kidney Disease
https://www.medscape.com/viewarticle/952953

Jun 11th, 2021 - A prolonged course of antibiotic therapy dramatically reduces the risk of recurrence in patients with renal cyst infections in the context of autosomal dominant polycystic kidney disease (ADPKD), a new study indicates. However, lipid-soluble antib...

see more →

Patient Education  19 results see all →